Correlation Between Veracyte and Denali Therapeutics

Can any of the company-specific risk be diversified away by investing in both Veracyte and Denali Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Denali Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Denali Therapeutics, you can compare the effects of market volatilities on Veracyte and Denali Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Denali Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Denali Therapeutics.

Diversification Opportunities for Veracyte and Denali Therapeutics

0.65

Correlation Coefficient

Veracyte  Denali Therapeutics

Poor diversification

The 3 months correlation between Veracyte and Denali is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Denali Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Denali Therapeutics and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Denali Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Denali Therapeutics has no effect on the direction of Veracyte i.e., Veracyte and Denali Therapeutics go up and down completely randomly.

Pair Corralation between Veracyte and Denali Therapeutics

Given the investment horizon of 90 days Veracyte is expected to generate 1.11 times more return on investment than Denali Therapeutics. However, Veracyte is 1.11 times more volatile than Denali Therapeutics. It trades about -0.29 of its potential returns per unit of risk. Denali Therapeutics is currently generating about -0.41 per unit of risk. If you would invest  4,506  in Veracyte on December 3, 2024 and sell it today you would lose (1,150) from holding Veracyte or give up 25.52% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Denali Therapeutics

Veracyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days Veracyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Denali Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Denali Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Pair Trading with Veracyte and Denali Therapeutics

The main advantage of trading using opposite Veracyte and Denali Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Denali Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Denali Therapeutics will offset losses from the drop in Denali Therapeutics' long position.

The idea behind Veracyte and Denali Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.